Bundibugyo Ebola Outbreak Spreads in Congo
Analysis based on 7 articles · First reported May 18, 2026 · Last updated May 20, 2026
The Bundibugyo ebolavirus outbreak, for which there is no approved vaccine, poses a significant threat to global health and could negatively impact the healthcare and pharmaceutical industries. Companies involved in vaccine and therapeutic development for emerging infectious diseases may see increased attention, while those in affected regions like the Democratic Republic of the Congo and Uganda could face economic disruption.
A deadly outbreak of the Bundibugyo ebolavirus is spreading in the Democratic Republic of the Congo and Uganda, prompting the World Health Organization to declare an international health emergency on May 17, 2026. This particular strain of Ebola has no approved vaccines or therapeutics, unlike the more common Zaire ebolavirus. The United States — Centers for Disease Control and Prevention is transferring exposed Americans from Congo and the United States has banned travelers from affected countries. The outbreak has already caused 246 suspected cases and 80 deaths in the Democratic Republic of the Congo's Ituri province and has reached Kampala, Uganda's capital. The delay in detection, due to rapid field tests calibrated for the Zaire ebolavirus, and the highly mobile population in conflict-ridden regions, are compounding the danger of widespread transmission.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard